Introduction
Platelets play an essential role in hemostasis by the formation of a primary hemostatic plug to avoid excessive blood loss upon vessel injury (1, 2) . In contrast, uncontrolled platelet activation upon rupture of an atherosclerotic plaque is responsible for acute vessel occlusion, leading to myocardial infarction or stroke (3, 4) .
Injury of the endothelium leads to exposure of extracellular matrix proteins that serve as substrates to initiate the adhesion and activation of circulating platelets by the engagement of specific receptors (2) . vWF binds the platelet-specific GPIb-V-IX complex, collagens bind the glycoprotein receptor GPVI and integrin α2β1, and fibronectin engages both integrin α5β1 and laminin α6β1 (5) . vWF binding to GPIb is essential for platelet recruitment to the vessel wall and initial adhesion in arterioles and stenotic arteries (6) . Engagement of GPVI by collagen leads to platelet activation important for stable platelet adhesion mediated by integrin αIIbβ3 binding to vWF and fibrinogen (7, 8) and release of platelet granules. Central for irreversible platelet activation is the release of soluble agonists such as thromboxane and ADP because they increase platelet activation by binding to G proteincoupled receptors (9, 10) .
Primary hemostasis is essential for a first coverage of injured vessels but not sufficient for thrombus growth and stability (5). Platelet activation followed by blood coagulation and thrombin generation is crucial for the formation of stable arterial thrombi. Platelets play an important role in these processes because they provide a procoagulant surface by exposing phosphatidylserine (PS) to allow assembly of coagulation complexes on their plasma membrane. So far, it is known that PS is exposed by the protein scramblase, which does only require an increased Ca 2+ concentration but no energy, and simultaneous Ca 2+ -induced inactivation of translocase and flippase. This happens, for example, during early apoptosis (11) . Platelets support fibrin formation and regulate the retraction of fibrin clots (12) .
Red blood cells (RBCs) have been described as participating in hemostasis by influencing rheology. In flowing blood, platelets are pressed against the vessel wall leading to a higher concentration of platelets. Thus, an increase in the hematocrit is accompanied by improved hemostasis, especially upon anemia (13) (14) (15) (16) . In 1961, Hellem and colleagues cited platelet adhesiveness as the most important platelet function in hemostasis (13) . The authors cite a study from Duke from 1910 in which direct transfusions were administered to patients with anemia Red blood cells (RBCs) influence rheology, and release ADP, ATP, and nitric oxide, suggesting a role for RBCs in hemostasis and thrombosis. Here, we provide evidence for a significant contribution of RBCs to thrombus formation. Anemic mice showed enhanced occlusion times upon injury of the carotid artery. A small population of RBCs was located to platelet thrombi and enhanced platelet activation by a direct cell contact via the FasL/FasR (CD95) pathway known to induce apoptosis. Activation of platelets in the presence of RBCs led to platelet FasL exposure that activated FasR on RBCs responsible for externalization of phosphatidylserine (PS) on the RBC membrane. Inhibition or genetic deletion of either FasL or FasR resulted in reduced PS exposure of RBCs and platelets, decreased thrombin generation, and reduced thrombus formation in vitro and protection against arterial thrombosis in vivo. Direct cell contacts between platelets and RBCs via FasL/FasR were shown after ligation of the inferior vena cava (IVC) and in surgical specimens of patients after thrombectomy. In a flow restriction model of the IVC, reduced thrombus formation was observed in FasL -/-mice. Taken together, our data reveal a significant contribution of RBCs to thrombosis by the FasL/FasR pathway.
shorten bleeding time in thrombocytopenic rabbits. Saniabadi proposed in 1985 that manipulating the hematocrit is a useful therapeutic option in the control of thrombotic and bleeding tendencies (18) . Today, the German guidelines for polytrauma and treatment of seriously injured persons (Kurzversion der S3 -Leitlinie Polytrauma/Schwerverletzten-Behandlung) dictate that the hematocrit be increased to a minimum 7-9 g/dl (Chapand thrombocytopenia. They claimed that RBCs influence the hemostatic mechanism because bleeding time in patients with severe anemia was prolonged. Livio and colleagues investigated uremic patients who are often anemic (15) . They observed that bleeding times in uremic patients are profoundly influenced by anemia. Blajchman et al. were able to confirm the clinical data in experimental animals (17) . They found that RBC transfusions 6 to 4 × 10 6 RBCs/μl, left to right) added to PRP in comparison with whole blood. Data are given for 3 shear rates of 150 s -1 (black column), 1,000 s -1 (gray column), and 1,700 s -1 (white column). Blood components as indicated below and shear rates as shown on the left. (C) Effect of WBCs on thrombus formation under flow. Representative images of surface coverage of whole blood and PRP in the absence and presence of WBCs (7 × 10 3 WBCs/μl and >15 × 10 4 WBCs/μl, respectively). Scale bar: 50 μm. (D) Quantitative analysis of surface coverage per visual field. (E and F) Thrombus formation using PRP and fixed RBCs. Bar graphs depict mean values ± SEM. n = 3, all experiments. ***P < 0.001 by Student's t test. PRP, platelet-rich plasma; RBC, red blood cell.
; Supplemental Figure 1 ). , respectively. The addition of 4 × 10 6 RBCs/μl to PRP induced 3-dimensional thrombus formation, as observed with whole blood that served as positive control (Supplemental Videos 1 and 3). In contrast, high platelet concentrations (PRP with 4 × 10 6 platelets/μl) did not result in robust thrombus formation under flow (Supplemental Figure 1) . Because RBCs play an important role in rheology, we performed fixation of 4 × 10 6 /μl RBCs and perfused them together with PRP through the chamber to preserve rheology but to avoid any responses of RBCs upon blood perfusion. Again, we did not observe 3-dimensional thrombus formation and only platelet aggregates were detected ( Figure 1 , E and F). These data suggest that RBCs might have an active role in thrombus formation. Raising the hematocrit to 75% (8 × 10 6 RBCs/μl) did not further increase platelet adhesion and thrombus formation (Supplemental Figure 1 , D and E) and the addition of old RBCs (>40 days after blood withdrawal) did not result in altered thrombus formation under flow (Supplemental Figure 1, F and G) .
A small population of RBCs in platelet-rich thrombi is sufficient to support thrombus formation under flow. To characterize the impact of RBCs in thrombus formation under flow, we compared the cellular components of whole blood and thrombi that were formed under flow conditions. Blood cells in thrombi were dissolved in Accutase to isolate individual cells of the thrombus and analyzed by flow cytometry according to cell morphology and cell-specific membrane proteins using cell-type-specific antibodies ( Figure 2A ). While greater than 94% of cells in whole blood are of RBC origin, we only found less than 2% RBCs in thrombi that were formed under flow conditions using whole blood and shear rates of 150 and 1,000 s -1 . The analysis of thrombi by toluidine blue staining ( Figure 2B ) and scanning electron microscopy (SEM; Figure 2C ) revealed that only very few RBCs are incorporated into a thrombus, confirming the data from flow cytometry. Analysis of thrombi isolated from C57BL/6 mice that underwent FeCl 3 -induced injury of the carotid artery showed that a small number of RBCs are located within a thrombus also in vivo (Figure 2D ). In fact, these RBCs are located in small islands within the thrombus ( Figure 2D ).
To test if hemoglobin influences thrombus formation under flow, we perfused PRP supplemented with 13 mg/ml hemoglobin through the chamber and analyzed thrombus formation ( Figure 2 , E and F). No thrombus formation was observed. However, control experiments revealed that no hemoglobin was released upon platelet adhesion and thrombus formation under flow (Supplemental Figure 1) .
To investigate the molecular mechanisms of RBCs and platelets important for thrombus formation, we prepared ghosts. Ghosts have an intact membrane but do not contain any metabter 2.16, 2.108) and that massive transfusion therapy be induced with fresh frozen plasma, RBCs, and platelets at the ratio of 4:4:1 (Chapter 2.16, 2.110).
Besides rheological effects, different mechanisms underlying RBCs' ability to influence hemostasis have been described, e.g., by the supply of ADP, ATP, or NO (19) (20) (21) (22) . Recent data provide evidence that RBCs are able to expose PS on their membrane and contribute to the generation of thrombin (23) (24) (25) . However, a direct contribution of RBCs to arterial thrombus formation and the impact of RBCs in platelet activation and thrombus formation are not well defined. The present study thus explored the active role of RBCs and the relevant mechanisms critical for platelet function and thrombus formation in vitro and in vivo.
Results

RBCs are essential for 3-dimensional thrombus formation under flow ex vivo.
To investigate RBC-driven mechanisms in thrombus formation, we analyzed platelet adhesion and thrombus formation under flow using a flow chamber system. Platelet-rich plasma (PRP) was supplemented with different concentrations of RBCs RBCs support occlusive thrombus formation ex vivo and in vivo. In a further set of experiments, thrombus formation was investigated in another ex vivo model, where occlusion of capillaries was analyzed (Figure 3, A-D) . In all experiments where PRP was used, full occlusion of the collagen-coated capillaries was significantly delayed compared with whole blood. Full occlusion of the capillaries was achieved within 10.68 ± 0.42 minutes using whole blood compared with 19.16 ± 1.82 minutes using PRP (P = 0.0027). Because PRP and whole blood have different total cell concentrations we also performed experiments with PRP and fixed RBCs (4 × 10 6 ) to avoid differences in rheology (Figure 3D , unaltered size of fixed RBCs is shown in Supplemental Figure 3A ). Again, we measured significantly delayed occlusion of the capillary where PRP and fixed RBCs were used compared with PRP and fresh untreated RBCs (4 × 10 6 ; 8.86 ± 0.64 minutes using PRP and fresh RBCs compared with 20.14 ± 5.71 minutes using PRP and fixed RBCs, P = 0.0486).
To investigate the impact of RBCs in hemostasis and arterial thrombus formation in vivo, we used anemic mice. To achieve anemia, 200 μl blood was taken from C57BL/6 mice on 2 consecutive days to reduce the hematocrit to 21%-28% (ca. 10 g/dl, Supplemental Figure 3 , B and C). We then transfused PRP alone or PRP (up to 45 × 10 4 /μl) with RBCs (number of RBCs until a hematocrit of ~40% was reached) to anemic mice (total platelet counts in the circulation of control and anemic mice were similar after transfusion) and analyzed tail bleeding times as well as arterial thrombus formation in vivo. The determination of bleeding times by amputating the tail tip of mice resulted in arrest of bleeding after 144.2 ± 11.2 (PRP + RBCs) versus 515.3 ± 112.6 (PRP) seconds, providing strong evidence that increased hematocrit is important for normal hemostasis ( Figure 3E ). To investigate if reduced hematocrit affects occlusive arterial thrombus formation, the right carotid artery was injured by topical application of 15% FeCl 3 and blood flow was monitored by an ultrasonic flow probe. As shown in Figure 3F , the onset of thrombus formation as detected by the formation of small aggregates was not different between control and anemic mice, although a slight but not significant increase was measured in anemic mice (mean time: PRP + RBCs 245 ± 61.8 seconds; PRP 420 ± 74.5 seconds, P = 0.1207). However, anemic mice showed significantly enhanced occlusion times compared with control mice (mean time: PRP+RBCs 537.5 ± 111.3 seconds; PRP 1,005 ± 56.1 seconds, P = 0.009, Figure 3F ), suggesting that the hematocrit influences platelet adhesion and aggregate formation at the injured vessel wall in vivo. Accordingly, only very few RBCs were present within the thrombus of anemic mice compared with control mice ( Figure 3G ). To investigate if increased hematocrit affects hemostasis or arterial thrombosis, we increased the hematocrit (>50%; Supplemental Figure 3D ) in mice by intravenous injection of fresh RBCs from donor mice from the same genotype and determined bleeding times in these mice ( Figure 3H ). Mice with increased hematocrit (HCT+) did not show altered hemostasis compared with control mice. Along these lines, arterial thrombosis was not altered in mice with increased hematocrit, as shown by comparable occlusion times in mice with increased hematocrit and control mice after FeCl 3 -induced injury of the carotid artery ( Figure 3I ).
RBCs facilitate thrombin generation and PS exposure of RBCs is important for arterial thrombus formation on collagen.
RBCs are known to expose PS on their membrane and contribute to the generation of thrombin (23) (24) (25) . To elucidate whether RBCs provide a procoagulant surface we performed flow chamber experiments with PRP and 4 × 10 6 /μl RBCs or ghosts and incubated ghosts with annexin V before perfusion to neutralize exposed PS on the surface of cells (26) . As a result, thrombus formation was strongly reduced when annexin V was added to ghosts before PRP and ghosts were mixed and perfused through the flow chamber ( Fig Figure 2D ) and anemic mice (middle and lower panel) are shown. Scale bars: 50 μm (upper and middle panel) and 20 μm (lower panel). (H) Bleeding times of mice that received RBC injections to increase the hematocrit were analyzed. (I) Time to occlusion in mice with increased hematocrit was determined after injury of the carotid artery with FeCl 3 (n = 9-10). HCT+, mice with increased hematocrit. Data are the mean ± SEM. *P < 0.05, **P < 0.01 by Student's t test.
in Figure 5A , RBCs are located within the thrombus, as already shown in Figure 2 . Furthermore, we found RBCs close to platelets and with direct contact to platelets. Flow cytometric analysis of static experiments using PRP incubated with fresh RBCs demonstrated that a small subpopulation of RBCs and platelets interact with each other because these cells were positively labeled for the platelet marker GPIbα and the RBC marker CD235a ( Figure 5B ). Comparable results were obtained with ADP-stimulated platelets (data not shown). To disclose the underlying mechanisms, we incubated RBCs with the supernatant of collagen-related peptidestimulated (CRP-stimulated) platelets and measured annexin V binding of RBCs. As expected, no increase in annexin V binding was observed ( Figure 5C ). However, experiments using PRP and thus intact platelets revealed a significant increase in PS exposure of RBCs, providing further evidence that a direct cell contact between platelets and RBCs is necessary to induce PS exposure of RBCs. Further experiments using aspirin and clopidogrel to inhibit thromboxane formation or ADP signaling via the ADP receptor P2Y 12 , respectively, demonstrated that neither thromboxane nor P2Y 12 plays a major role in platelet-mediated induction of PS exposure of RBCs (Supplemental Figure 6A ). All these data prompted us to look for a receptor-mediated interaction between platelets and RBCs. Recently, the platelet receptors CD36 and CXCL16 have been shown to bind to PS exposed at the RBC membrane (27) . To analyze if these receptors influence the induction of PS exposure of RBCs, we performed flow chamber experiments. Supplemental Figure 6 demonstrates that neither blood from Cd36-knockout mice nor treatment of Cd36-WT blood with inhibitory antibodies against CD36 and CXCL16 influences PS exposure of RBCs (Supplemental Figure 6 , B-D).
Fas receptor-mediated cell-cell contact between platelets and RBCs is essential for PS exposure of RBCs upon thrombus formation.
Fas receptor (FasR, CD95) signaling in RBCs is known to induce an apoptotic signal via activation of caspase 3 leading to PS externalization in human RBCs (28) Figure 6, C and D) , while the FasR-inhibiting antibody had no effect in PRP alone (data not shown). To investigate the tion of RBCs in the flow chamber led to a stronger annexin V signal in flow cytometry. The analysis of ghosts revealed high PS exposure of these cells that was significantly reduced by pretreatment of ghosts with annexin V before starting the flow chamber run ( Figure 4E ). In control experiments, we confirmed that treatment with Accutase leads to almost complete dissolution of cells from the coverslip and we were able to exclude any effect of Accutase treatment on PS exposure of RBCs (Supplemental Figure 5 ). Flow cytometric analysis confirmed an increased number of CD235-positive cells when we perfused ghosts through the flow chamber compared with different approaches with fresh RBCs or pretreatment of ghosts with annexin V ( Figure 4F ). The change in mean fluorescence intensity (MFI) of annexin V binding to RBCs demonstrated almost no differences when comparing RBCs before perfusion through the chamber and thereafter (RBCs that leave the chamber without being recruited to the thrombus, Figure 4G ). These data confirmed that most RBCs within a thrombus expose PS on their surface, while the vast majority of RBCs from the flow through do not expose PS (Figure 4 , E-G).
Next, we determined thrombin generation in PRP and PRP supplemented with RBCs after stimulation of platelets with either thrombin (Figure 4 , H and J) or ADP ( Figure 4 , I and J). Thrombin was generated faster, as demonstrated by shorter lag time, and the thrombin peak was increased when PRP was supplemented with RBCs compared with PRP alone (Figure 4 , H-J).
Cell-cell contact between platelets and RBCs is crucial for RBCplatelet interaction. To determine which signal or mechanism is responsible for the induction of PS externalization of RBCs, we perfused whole blood through the flow chamber and allowed thrombus formation on a collagen matrix. Thrombi were then analyzed by transmission electron microscopy (TEM). As shown To analyze whether FasR on RBCs has any impact on arterial thrombosis in vivo, we analyzed WT mice treated with FasR-blocking antibody (20 μg/mouse) in a thrombosis model where injury of mesenteric arterioles was induced by FeCl 3 . Platelet adhesion and thrombus formation at sites of vessel injury were induced by topical application of 20% FeCl 3 on exposed mesenteric arterioles. Complete vessel occlusion occurred in control mice within 1,420 ± 142.6 seconds, with an occlusion rate of 100%. In contrast, we never observed occlusion of mesenteric arterioles in mice treated with the inhibitory FasR antibody, suggesting that these mice are protected against arterial thrombosis ( Figure 6 , I and J, and Supplemental Videos 5 and 6). In contrast, hemostasis, as analyzed by tail bleeding experiments, was not altered in mice that received FasR-blocking antibody ( Figure 6K ). Taken together, these results clearly show that interfering with platelet-RBC interactions by blocking FasR might be a promising new therapeutic strategy.
Platelet Figure 7A ). While platelet activation did not lead to a significant increase in FasL externalization, we detected a significant increase in FasL expression on resting and activated platelets in the presence of RBCs. The presence of WBCs did not alter FasL expression of resting platelets but did alter that of activated platelets (Supplemental Figure 7E) . In another set of experiments, platelet adhesion on immobilized FasR showed an increase of ADP-stimulated adherent platelets that was significantly reduced when platelets were treated with human decoy receptor 3 (hDcR3), while no differences were observed upon platelet adhesion to collagen (Figure 7, B-D) . hDcR3 binds to FasL without any signal transduction capabilities and prevents To analyze if platelets have an activated phenotype in the presence of RBCs, we determined P-selectin exposure (degranulation marker) and activated integrin αIIbβ3 (PAC-1 binding) by flow cytometry (Supplemental Figure 7, A and B) . We did not detect any Figure 7E ). Under flow conditions, platelet adhesion and 3-dimensional thrombus formation were significantly reduced in hDcR3-treated whole blood (Figure 7, F and G) . In addition to a reduced surface cov- (Figure 8, C and D) . Moreover, we determined the number of RBCs in thrombi using the RBC marker TER-119 (red) and the platelet marker GP9 (green). As shown in Figure 8 , E-G, the number of RBCs in thrombi was significantly reduced when we perfused whole blood from FasL -/-or FasR -/-mice through the chamber. Annexin V binding to RBCs and platelets in the absence or presence of RBCs was measured by flow cytometry under static conditions. As shown in Figure 9 , the incubation of ADP-activated platelets from WT or FasL -/-mice with WT RBCs as well as WT
Genetic deletion of FasR or FasL is responsible for altered PS exposure and thrombus formation in vitro and in vivo.
To confirm the inhibitory experiments with FasR antibody and hDcR3, we analyzed FasL-and FasR-knockout mice. First, we measured platelet and RBC counts, hematocrit, and basal levels of PS exposure at the RBC membrane in knockout mice and found no significant alterations between the different mouse lines (Supplemental Figure 8 , A-C).
Given that we analyzed human platelets with FasR antibody and hDcR3, we now analyzed thrombus formation under flow with murine blood and FasR-inhibiting antibody to confirm the human data ( Figure 8A ). Significantly decreased formation of 3-dimensional thrombi was found when we perfused whole blood supplemented with FasR antibody through the chamber using a shear sel injury that resulted in prompt initiation of thrombus formation ( Figure 10A ) and complete vessel occlusion in WT mice, while most of FasR -/-mice showed a delay in the initiation of thrombus formation and no occlusion at the end of the observation period of 40 minutes ( Figure 10B ). An even more pronounced phenotype was observed with FasL -/-mice that showed no aggregate or thrombus formation at all; thus, no occlusion of the injured vessel was observed in these mice (occlusion time > 40 minutes, Figure  10 , A-D). Furthermore, thrombus size at different time points was significantly reduced in FasR -/-mice, while no thrombi were observed in FasL -/-mice compared with WT controls ( Figure 10E ). To confirm the importance of platelet FasL in thrombus formation in vivo, we analyzed mice with a cell-specific knockout of FasL in platelets using PF4-Cre + FasL fl/fl mice. As shown in Figure 10F the thrombi was significantly enhanced compared with resting platelets, but only moderately increased compared with CRP-activated platelets ( Figure 11D Figure 11, E and F) . Interestingly, no differences were observed in annexin V binding to activated platelets ( Figure 11G ). Flow cytometric analysis of whole blood from patients revealed that P-selectin and PS exposure of platelets was significantly enhanced compared with healthy volunteers (Supplemental Figure 9 ), while no difference in FasL exposure was observed. We next compared RBC-rich thrombi and platelet-rich thrombi and found no alterations in FasL externalization ( Figure  11H ). However, annexin V binding to RBCs in platelet-rich thrombi was significantly enhanced compared with PS exposure of RBCs in RBC-rich thrombi ( Figure 11I ). PS externalization of platelets was significantly higher in RBC-rich thrombi ( Figure 11J ). Taken together, these data provide the first evidence to our knowledge that cell-cell contact between platelets and RBCs via FasL-FasR interaction is also relevant under pathological conditions.
Discussion
In this study, we have shown that RBCs are essential for effective thrombus formation in vitro and in vivo, because a reduced number of RBCs results in attenuated hemostasis and prolonged occlusion times in anemic mice. Besides effects of RBCs on rheology conditions, a small population of RBCs is sufficient to support platelet-mediated thrombus formation by providing a procoagulant surface. Mechanistically, in a direct cell-cell contact between platelets and RBCs PS exposure of RBCs occurs, mediated through FasL-induced activation of FasR, followed by thrombin generation and platelet activation ( Figure 11K ). Inhibition or genetic deletion of FasR prevents 3-dimensional thrombus formation on collagen under flow ex vivo, arterial and venous thrombosis, and RBC-platelet interaction after IVC ligation in vivo, suggesting that FasL-FasR interaction is essential for thrombus formation.
Mice with global FasL deficiency as well as platelet-specific loss of FasL confirmed the importance of platelet FasL for the induction of PS exposure at the RBC membrane and thrombus formation in vivo. High FasL and PS exposure of platelets and RBCs in arterial thrombi of patients provide evidence that FasL-FasR-mediated cell contact between platelets and RBCs represents a pathophysiological mechanism as well. RBCs have been linked to thrombus formation for decades. They have been described to play a passive role in hemostasis by physical and chemical effects on the interaction between platelets and the vessel wall (16, 32) . In flowing blood, RBCs displace platelets to the vessel wall, to induce contact of platelets with prothrombotic extracellular matrix proteins exposed upon vessel injury. In the FeCl 3 mouse model of arterial thrombosis, RBCs were shown to participate in thrombosis by supporting platelet adhesion to the intact endothelium (33) . A reduced hematocrit is accompanied by prolonged bleeding times in humans and experimental animals, providing a pathophysiologically reasoned rationale to reduce the as controls. Figure 10J ). In a flow restriction model of the IVC, venous thrombus formation, as measured by thrombus weight, was not altered in mice treated with FasR-blocking antibody, although the incidence of thrombus formation was reduced: 30% incidence compared with 60% in IgG control mice ( Figure  10L) . Therefore, the incidence of thrombus formation (50% of IgG-treated mice) rather than the thrombus weight represents differences between FasR antibody-and IgG-treated mice. In contrast, venous thrombus formation was significantly reduced in FasL -/-compared with control mice, while the incidence of thrombus formation was slightly enhanced in these mice (WT vs. FasL -/-: 15.06 mg ± 3.91 vs. 5.683 ± 1.277, P = 0.0446; Figure 10M ).
Normal hemostasis upon FasR or FasL deficiency was observed when tail bleeding times of WT, FasR -/-, and FasL -/-mice were measured ( Figure 10N ). In line with these results, plateletspecific FasL-knockout mice were described to show no differences in bleeding times compared with controls as shown by Schleicher and colleagues (31) .
FasL-FasR-mediated PS externalization of RBCs is relevant under pathological conditions.
To investigate whether platelet-mediated PS externalization on the RBC membrane via FasL-FasR interaction influences arterial thrombosis in humans, we analyzed thrombi that were isolated from patients who underwent surgical thrombectomy (Table 1) . Histological sections from these thrombi were stained with hematoxylin and eosin and characterized for thrombus morphology ( Figure 11A ). We found RBCs in small islands within the thrombus, as observed in mice after injury of the carotid artery ( Figure 2D ). TEM analysis of thrombi provided strong evidence for a direct contact between RBCs and platelets under pathological conditions ( Figure 11B ), as observed in thrombi that resulted from platelet adhesion and thrombus formation under flow ( Figure 5A ). Flow cytometric analysis of cell types within the thrombi revealed that 56.74% ± 4.64% RBCs and 42.37% ± 4.62% platelets were localized to the thrombi ( Figure  11C ). Next, we measured platelet activation and annexin V binding to platelets and RBCs isolated from these thrombi and compared the data with freshly isolated resting and activated platelets and RBCs from healthy volunteers. P-selectin exposure of platelets in production, and ADP release when RBCs were present in platelet suspensions (22, 40, 41) . Here, we did not detect increased P-selectin exposure or integrin activation (Supplemental Figure  7) . However, a direct mechanism for the induction of PS exposure on RBCs in a growing thrombus is currently unknown; nor has a direct contribution of RBCs to arterial thrombus formation by PS exposure, thrombin generation, or platelet activation been shown to date. Thus, we believe that the role of the FasL-FasR interaction in mediating platelet-RBC contacts upon adhesion to the injured vessel and arterial and venous thrombus formation is a completely novel element in platelet activation and aggregate formation. Here, we show that the death receptor FasR (CD95) on RBCs is essential for thrombus formation, while inhibition or genetic deletion of FasR protects mice from arterial thrombosis. FasL is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family and binds to FasR to induce apoptosis (29, 42, 43) . Furthermore, FasL-FasR interactions play an important role in the regulation of the immune system and the progression of cancer (44) (45) (46) (47) . FasL is expressed by activated T cells and natural killer cells and induces apoptosis of target cells via FasR (48) . Activated platelets expose FasL on their surface and induce apoptosis in Fas-positive tumor cells in vitro (49) and in a mouse model of stroke in vivo (31) . This study reveals that platelet FasL is a ligand for FasR on the RBC membrane critical for the cell-cell interaction between RBCs and platelets. Interestingly, the expression of FasL on the platelet membrane ( Figure 7A ) as well as FasR expression on RBCs (Supplemental Figure 6 ) had already increased under resting conditions when platelets and RBCs were coincubated, suggesting that the cells influence the expression of receptors of the other cell. hDcR3 is a TNF-R1-and FasR-related death receptor and does not transduce apoptotic signals but competes with the death receptors for ligand binding to inhibit apoptosis (30, 50) . It is noteworthy that hDcR3-mediated reduction of thrombus formation and PS exposure of RBCs within the thrombus is significantly reduced, but to a lesser extent than that with FasR inhibition. The same observation was made with FasL -/-platelets ( Figure 8 , C and D), suggesting that another ligand on the platelet membrane might be able to activate FasR on RBCs. Interestingly, PS exposure of RBCs was shown to be not dependent on caspases (Supplemental Figure 6 , G and H), although caspase activation following FasL binding to FasR has been shown to reflect a general mechanism to induce apoptosis in target cells, especially in the immune system (47) and in cancer (46) . However, in RBCs there might be another mechanism that translates FasR activation to PS exposure. In acute leukemia, an alternative pathway through TRADD and TRAF initiates a phosphorylation cascade leading to the activation of JNK and phosphorylation of p53 and c-Jun, which induces apoptosis through multiple mechanisms including Bdl-2 family proteins (51) . An acid sphingomyelinase is also activated in response to FasR activation, leading to ceramide production and cell stress that also might account for PS exposure at the RBC membrane (52) .
In recent years, it has become increasingly evident that different cellular processes are involved in hemostasis and thrombosis (53, 54) . In this study, we observed that blocking FasR with an antibody (Figure 6K ) or deficiency of either FasL or FasR does not lead to impaired hemostasis ( Figure 10N ) but protects against risk of bleeding by normalizing the hematocrit with RBC transfusions (15, 17, 18, 34) . In this study, the analysis of thrombus formation with PRP supplemented with fixed RBCs (Figure 3D and Supplemental Figure 1 ) suggests that RBCs not only influence rheology but play an active role in supporting thrombus formation. Different mechanisms for RBCs and their role in hemostasis have been described. RBCs release ADP, ATP, and NO and thus might influence hemostasis by platelet activation (19) (20) (21) (22) . In 1961, Gaarder and colleagues found ADP released by RBCs to be relevant for platelet adhesion (20) and platelet aggregation (35) . More recent data link RBCs with PS exposure (28) and suggest prothrombotic properties of RBCs (23, 24, 36) . Here, we directly provide evidence for the contribution of RBCs to thrombin generation because the supply of RBCs to PRP significantly increased the height of the thrombin peak and shortened the time when thrombin generation was initiated (Figure 4 , H-J). However, less is known so far about the mechanisms of PS exposure of RBCs. Red cell ICAM-4 was suggested to be a novel ligand for integrin αIIbβ3 on platelets (37, 38) . This was strengthened by inhibitory experiments with decreased thrombin formation (39) . Moreover, adhesion of RBCs to immobilized platelets depends on PS exposure of RBCs and the PS receptors CD36 and CXCL16 (27) . To date, it is still not clear how RBCs come into first contact with platelets to induce FasL/FasR signaling. However, decreased incorporation of RBCs into a thrombus was observed when the interaction between ICAM-4 and integrin αIIbβ3 was inhibited (39) .
PS exposure of RBCs led to increased annexin V binding to platelets ( Figure 6, B and H) . The activation of platelets by RBCplatelet interactions has already been shown by different groups. In contrast to this study, the authors provided evidence for enhanced integrin activation, P-selectin exposure, thromboxane ). It is tempting to speculate that pathological high shear rates might affect RBC-platelet interaction, as has been shown by Turitto and Weiss (16) . Under pathological conditions, increased procoagulant activity of RBCs was measured in patients with sickle-cell disease and with nephrotic syndrome (56, 62) . Interestingly, RBC-rich thrombi contain more inflammatory cells in patients with ST-elevation myocardial infarction with impaired myocardial reperfusion (63) . So far, the consequences of hypoxia or atherosclerotic vessels with decreased vessel lumen and high shear rates for platelet-RBC interactions are not known but might also be relevant, e.g., upon myocardial infarction or stroke.
However, high levels of PS externalization on platelets and RBCs in arterial thrombi of patients might also be due to the apoptotic character of these cells because some patients had already suffered from arterial thrombosis for several hours or days (for details see Table 1 ).
arterial thrombosis, while anemia leads to increased occlusion times and impaired hemostasis after vessel injury (Figure 3 , E and F). This suggests that the rheology-dependent impact of RBCs in thrombus formation is different from the FasL-FasR interaction between platelets and RBCs.
The analysis of thrombi isolated from patients by thrombectomy suggests that FasL-FasR-mediated interaction between platelets and RBCs might be relevant under pathological conditions. Polycythemia patients with high RBC counts as well as patients with inherited RBC abnormalities suffer from thrombotic complications and exhibit cardiac and cerebral thrombosis with abnormal PS exposure on RBCs (55) (56) (57) (58) (59) (60) . Moreover, a correlation between infarct size and hematocrit was shown in patients with carotid occlusion and completed strokes (61) . Our studies did not confirm a relationship between increased numbers of RBCs and thrombus formation because perfusion of PRP and 8 × 10 6 RBCs/μl did not result in accelerated thrombus formation under flow (Supplemental Figure 1, D and E) . Moreover, mice with increased hematocrit Taken together, our results indicate that RBCs are essential for hemostasis and arterial as well as venous thrombosis. FasL-FasRmediated cell-cell contact between platelets and RBCs mediates PS externalization on the RBC membrane critical for platelet activation and adhesion upon thrombus formation. The potential mechanism underlying the RBC-platelet interaction identified here is summarized in Figure 11K . Thus, interfering with the FasL-FasR interaction might be an innovative and promising approach for a completely novel antithrombotic strategy.
Methods
Animals. Specific pathogen-free C57BL/6J mice were obtained from Janvier Labs. littermate controls were analyzed for thrombus formation. Experiments were performed with male and female mice aged 2-4 months. Murine platelet preparation. Platelets were prepared as previously described (64, 65) . Blood was collected into trisodium citrate and centrifuged at 250 g for 5 minutes at room temperature. To obtain PRP, the supernatant was centrifuged at 50 g for 6 minutes. PRP was washed twice at 650 g for 5 minutes and the pellet was resuspended in Tyrode's buffer (136 mM NaCl, 0.4 mM Na 2 HPO 4 , 2.7 mM KCl, 12 mM NaHCO 3 , 0.1% glucose, 0.35% bovine serum albumin, pH 7.4) supplemented with prostacyclin (0.5 μM) and apyrase (0.02 U/ml). Before use, platelets were resuspended in the same buffer and incubated at 37°C for 30 minutes.
Study approval. All animal experiments were conducted according to the Declaration of Helsinki and German law for the welfare of animals. The protocol was reviewed and approved by the local
